Although it is a more global strategy to interfere with CRM1-dependent transport processes as it affects all proteins bearing a canonical NES in all cells, it seems to be a promising idea to use natural or synthetic compounds to block CRM1 and thus interfere with transport and localization of cancer-related proteins. The gene discussed is XPO1; the disease is cancer.